Form 4: Marinus Pharmaceuticals Officer Hulihan Reports Share Disposal and Option Termination Following Merger Agreement

Joseph Hulihan, Chief Medical Officer of Marinus Pharmaceuticals, reports the disposal of common stock and termination of stock options following the merger agreement with Immedica Pharma AB.

Summary

• Joseph Hulihan, Chief Medical Officer of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions occurring on February 7, 2025, and February 11, 2025, related to the merger agreement with Immedica Pharma AB.
• Hulihan disposed of 17,155 shares of common stock at $0.55 per share on February 7, 2025.
• On February 11, 2025, Hulihan disposed of 55,570 shares underlying Restricted Stock Units (RSUs) for a cash payment of $0.55 per share.
• All out-of-the-money stock options held by Hulihan were terminated as per the merger agreement, resulting in no payment to Hulihan for these options.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports transactions related to a previously announced merger. The termination of stock options without payment is a negative for the executive, but it's a standard consequence of the merger agreement.

Negatives

• Hulihan's stock options were terminated without any payment due to the merger agreement and the options being out-of-the-money.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger agreement.

Industry Context

This filing reflects the impact of a merger on the holdings of a company's executives, a common occurrence during such transactions. It indicates the completion of a step in the acquisition process.

Key Dates

Keywords

Form 4, Beneficial Ownership, Marinus Pharmaceuticals, MRNS, Joseph Hulihan, Immedica Pharma AB, Merger Agreement, Stock Options, Restricted Stock Units, Disposal